Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 9:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 1,961 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Gastric Clear all
Recruiting Not applicable Interventional

Enteral Anastomosis for the Treatment of Gastric Outlet Obstruction: A Randomized Controlled Study Comparing Endoscopic Versus Surgical Gastrojejunostomy

NCT05561907
View directory record Official record
Conditions
Gastric Outlet Obstruction
Interventions
Surgical gastrojejunostomy (SGJ), Endoscopic gastrojejunostomy (EGJ)
Procedure
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
New Brunswick, New Jersey • Manhasset, New York • New Hyde Park, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 28, 2026, 9:41 PM EDT
Completed Phase 1 Interventional Results available

TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers

NCT04306900
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
TTX-030, budigalimab and mFOLFOX6, TTX-030, budigalimab and docetaxel, TTX-030 and mFOLFOX6, TTX-030 and budigalimab, TTX-030, budigalimab, nab-paclitaxel and gemcitabine, TTX-030 and pembrolizumab, TTX-030, nab-paclitaxel and gemcitabine, Budigalimab and mFOLFOX6
Combination Product
Lead sponsor
Trishula Therapeutics, Inc.
Industry
Eligibility
18 Years to 110 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
26
States / cities
Scottsdale, Arizona • Duarte, California • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Oct 28, 2026, 9:41 PM EDT
Terminated Phase 2 Interventional Results available

Randomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With Documented Tumor Progression After Chemotherapy, or Where no Approved Therapy Exists

NCT00447226
View directory record Official record
Conditions
Cancer
Interventions
Oral lapatinib tablets or placebo tablets
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
20
States / cities
Denver, Colorado • Indianapolis, Indiana • Overland Park, Kansas + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2012 · Synced Oct 28, 2026, 9:41 PM EDT
Completed No phase listed Observational

Pharmacist-Driven Stress Ulcer Prophylaxis Minimization in the Intensive Care Unit

NCT06225167
View directory record Official record
Conditions
Stress Ulcer
Interventions
To evaluate the effectiveness and safety of a pharmacist-driven protocol to discontinue stress ulcer prophylaxis in ICU patients when it is no longer indicated according to pre-defined criteria.
Behavioral
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years to 85 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 28, 2026, 9:41 PM EDT
Withdrawn Not applicable Interventional

Validation of Esophageal Variceal Grading: A Comparative Study of Upper Gastrointestinal (GI) Endoscopy and Capsule Endoscopy

NCT00475592
View directory record Official record
Conditions
Esophageal and Gastric Varices
Interventions
Esophageal Capsule Endoscopy, Upper Gastrointestinal Endoscopy
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 24, 2017 · Synced Oct 28, 2026, 9:41 PM EDT
Terminated Phase 2 Interventional Results available

Pre-operative Adaptive Short Court Radiation Therapy in Gastric Cancer

NCT04162665
View directory record Official record
Conditions
Gastric Adenocarcinoma
Interventions
Adaptive short course radiation therapy, Standard of care chemotherapy regimen
Radiation · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
19 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 9, 2025 · Synced Oct 28, 2026, 9:41 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis

NCT00251719
View directory record Official record
Conditions
Esophagitis, Reflux, Esophagitis, Peptic
Interventions
Dexlansoprazole MR, Lansoprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
2,054 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
100
States / cities
Anniston, Alabama • Hueytown, Alabama • Huntsville, Alabama + 97 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2012 · Synced Oct 28, 2026, 9:41 PM EDT
Enrolling by invitation Not applicable Interventional

Premedication Gastric Ultrasound

NCT04130022
View directory record Official record
Conditions
Surgery
Interventions
Point-of-Care Ultrasound
Device
Lead sponsor
Kevin Spellman
Other
Eligibility
0 Years to 18 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 28, 2026, 9:41 PM EDT
Completed Phase 2 Interventional Results available

Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors

NCT05997056
View directory record Official record
Conditions
Neuroendocrine Tumors, NET, Pancreatic Neuroendocrine Tumor, Gastrointestinal Neuroendocrine Tumor, Pulmonary Neuroendocrine Tumor
Interventions
nab-sirolimus
Drug
Lead sponsor
Aadi Bioscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
4
States / cities
Newport Beach, California • Denver, Colorado • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 28, 2026, 9:41 PM EDT
Withdrawn No phase listed Observational

Collection of Biospecimen & Clinical Information in Patients w/ Gastrointestinal Cancers

NCT01031056
View directory record Official record
Conditions
Gastrointestinal Neoplasms, Gynecologic Cancers, Gynecologic Cancers Cervical Cancer, Gastric (Stomach) Cancer, Gastro-Esophageal(GE) Junction Cancer, Gastrointenstinal Stromal Tumor (GIST), Colon/Rectal Cancer, Colon/Rectal Cancer Colon Cancer, Colon/Rectal Cancer Rectal Cancer, Colon/Rectal Cancer Anal Cancer, Anal Cancer, Hepatobiliary Cancers, Hepatobiliary Cancers Liver, Pancreatic Cancer
Interventions
Blood Draw, Frozen Tumor Specimens
Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2099
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 28, 2012 · Synced Oct 28, 2026, 9:41 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Mechanism of Weight Loss After Endoscopic and Laparoscopic Sleeve Procedures

NCT04006002
View directory record Official record
Conditions
Weight Loss, Reflux
Interventions
Metabolic and Hormonal profile
Other
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 14, 2022 · Synced Oct 28, 2026, 9:41 PM EDT
Recruiting Phase 2 Interventional

AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

NCT06219941
View directory record Official record
Conditions
Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma
Interventions
AZD0901, 5-Fluorouracil, Leucovorin, l-leucovorin, Irinotecan, Nanoliposomal Irinotecan, Gemcitabine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Orange, California • Palo Alto, California • Santa Rosa, California + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 28, 2026, 9:41 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Atrial Fibrillation Ablation on Gastric Motility "The AF Gut Study"

NCT01396356
View directory record Official record
Conditions
Atrial Fibrillation Ablation Procedure
Interventions
GI procedures
Procedure
Lead sponsor
Dhanunjaya Lakkireddy, MD, FACC
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 10, 2013 · Synced Oct 28, 2026, 9:41 PM EDT
Recruiting Phase 1 Interventional

Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors

NCT06441331
View directory record Official record
Conditions
Somatostatin Receptor Positive, NETs, Lymphoma, Solid Tumor, CNS Tumors, Rhabdomyosarcoma, Peripheral Primitive Neuroectodermal Tumor, GIST
Interventions
Lutetium Lu 177-Edotreotide, Amino Acid Solution
Drug · Other
Lead sponsor
ITM Solucin GmbH
Industry
Eligibility
24 Months to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
5
States / cities
Palo Alto, California • San Francisco, California • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 28, 2026, 9:41 PM EDT
Active, not recruiting Phase 1 Interventional Results available

MAGE-A4ᶜ¹º³²T for Multi-Tumor

NCT03132922
View directory record Official record
Conditions
Urinary Bladder Cancer, Melanoma, Head and Neck Cancer, Ovarian Cancer, Non-Small Cell Lung Cancer, Esophageal Cancer, Gastric Cancer, Synovial Sarcoma, Myxoid Round Cell Liposarcoma, Gastroesophageal Junction
Interventions
Autologous genetically modified MAGE-A4ᶜ¹º³²T cells, Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation
Genetic · Radiation
Lead sponsor
USWM CT, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2032
U.S. locations
10
States / cities
Miami, Florida • Tampa, Florida • St Louis, Missouri + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 28, 2026, 9:41 PM EDT
Completed Phase 2 Interventional Results available

FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer

NCT01747551
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
Oxaliplatin, Leucovorin, Fluorouracil, Ziv-aflibercept
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced Oct 28, 2026, 9:41 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With Solid Tumors

NCT02009631
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer, Colon Cancer, Lung Cancer, Gastric Cancer, Solid Tumors
Interventions
Veliparib (ABT-888), Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Scottsdale, Arizona • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 20, 2017 · Synced Oct 28, 2026, 9:41 PM EDT
Recruiting Not applicable Interventional

Effect of Vagal Nerve Stimulation on Gastric Motor Functions

NCT06038929
View directory record Official record
Conditions
Depression, Epilepsy
Interventions
Vagal nerve stimulant
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Minneapolis, Minnesota • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 28, 2026, 9:41 PM EDT
Recruiting Phase 1Phase 2 Interventional

Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies

NCT03539822
View directory record Official record
Conditions
Gastric Cancer, Esophageal Adenocarcinoma, Hepatocellular Carcinoma, Colorectal Cancer
Interventions
Cabozantinib, Durvalumab, Tremelimumab
Drug
Lead sponsor
Anwaar Saeed
Other
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
2
States / cities
Westwood, Kansas • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 28, 2026, 9:41 PM EDT
Recruiting No phase listed Observational

The GAstric Precancerous Conditions Study

NCT04191551
View directory record Official record
Conditions
Gastric Cancer, Intestinal Metaplasia of Gastric Mucosa, Helicobacter Pylori Infection, Atrophic Gastritis
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
35 Years to 84 Years
Enrollment
600 participants
Timeline
2018 – 2028
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 28, 2026, 9:41 PM EDT
Terminated Not applicable Interventional Results available

Dermatome Electrical Stimulation on Individuals With Overweight and Class I Obesity

NCT03261531
View directory record Official record
Conditions
Obesity
Interventions
Transcutaneous electrical nerve stimulation (TENS)
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 28, 2026, 9:41 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Gut Microbiota Post Roux-en-Y Gastric Bypass Surgery

NCT02654496
View directory record Official record
Conditions
Obesity
Interventions
Meal challenge
Other
Lead sponsor
North Dakota State University
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 23, 2018 · Synced Oct 28, 2026, 9:41 PM EDT
Completed Phase 2 Interventional Results available

Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma

NCT00515411
View directory record Official record
Conditions
Gastroesophageal Junction Adenocarcinoma, Gastric Cancer
Interventions
Docetaxel, Leucovorin, Fluorouracil, Cisplatin, Docetaxel, Cisplatin, Fluorouracil, Neulasta, or Neupogen, Docetaxel, Leukvorin, Flurouracil, Cisplatin, Trastuzumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2018
U.S. locations
15
States / cities
Duarte, California • Pembroke Pines, Florida • Atlanta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2019 · Synced Oct 28, 2026, 9:41 PM EDT
Active, not recruiting No phase listed Observational

Intestinal Metabolic Reprogramming as a Key Mechanism of Gastric Bypass in Humans

NCT02710370
View directory record Official record
Conditions
Obesity, Diabetes Mellitus, Type 2, Endocrine System Diseases, Glucose Metabolism Disorders, Metabolic Diseases
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 28, 2026, 9:41 PM EDT